STOCK TITAN

[Form 4] Monopar Therapeutics Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) – Form 4 insider transaction filed for Chief Operating Officer Andrew Cittadine covering activity on 30 June 2025.

  • 6,863 common shares were issued to Cittadine upon the vesting of Restricted Stock Units (RSUs) granted on 2 Feb 2022, 1 Feb 2023 and 4 Mar 2025.
  • 2,990 shares were withheld for taxes (transaction code “F”), leaving a net 3,873 new shares.
  • Cittadine’s direct common-stock holding after the transactions is 45,858 shares; he also retains 43,001 unvested RSUs.
  • No open-market purchases or sales occurred; all activity relates to automatic RSU settlement (transaction code “M”).

The filing indicates a routine equity-compensation event rather than a discretionary purchase. While the COO’s ownership stake increases modestly, the economic outlay is zero; therefore, the signal for outside investors is generally neutral.

Monopar Therapeutics (MNPR) – Transazione insider Form 4 presentata per il Chief Operating Officer Andrew Cittadine relativa all'attività del 30 giugno 2025.

  • Sono state emesse 6.863 azioni ordinarie a Cittadine in seguito al vesting di Restricted Stock Units (RSU) concesse il 2 feb 2022, 1 feb 2023 e 4 mar 2025.
  • Sono state trattenute 2.990 azioni per tasse (codice transazione “F”), lasciando un netto di 3.873 nuove azioni.
  • La partecipazione diretta di Cittadine dopo le transazioni è di 45.858 azioni ordinarie; conserva inoltre 43.001 RSU non ancora vestite.
  • Non si sono verificate compravendite sul mercato aperto; tutta l’attività riguarda il regolamento automatico delle RSU (codice transazione “M”).

Il deposito indica un evento di compensazione azionaria di routine piuttosto che un acquisto discrezionale. Sebbene la quota del COO aumenti leggermente, il costo economico è zero; pertanto, il segnale per gli investitori esterni è generalmente neutro.

Monopar Therapeutics (MNPR) – Transacción insider Formulario 4 presentada para el Director de Operaciones Andrew Cittadine correspondiente a la actividad del 30 de junio de 2025.

  • Se emitieron 6,863 acciones ordinarias a Cittadine tras la consolidación de Unidades de Acciones Restringidas (RSU) otorgadas el 2 de feb 2022, 1 de feb 2023 y 4 de mar 2025.
  • 2,990 acciones fueron retenidas para impuestos (código de transacción “F”), quedando un neto de 3,873 nuevas acciones.
  • La participación directa en acciones ordinarias de Cittadine tras las transacciones es de 45,858 acciones; también conserva 43,001 RSU no consolidadas.
  • No hubo compras ni ventas en el mercado abierto; toda la actividad corresponde a la liquidación automática de RSU (código de transacción “M”).

El informe indica un evento rutinario de compensación en acciones más que una compra discrecional. Aunque la participación del COO aumenta modestamente, el gasto económico es cero; por lo tanto, la señal para los inversores externos es generalmente neutral.

Monopar Therapeutics (MNPR) – 내부자 거래 Form 4 제출 최고운영책임자(Andrew Cittadine)의 2025년 6월 30일 활동에 관한 내용입니다.

  • 6,863주 보통주가 2022년 2월 2일, 2023년 2월 1일, 2025년 3월 4일에 부여된 제한주식단위(RSU)의 권리 확정(vesting)에 따라 Cittadine에게 발행되었습니다.
  • 2,990주가 세금 원천징수(거래 코드 “F”)되어, 순수 3,873주가 신규 발행되었습니다.
  • 거래 후 Cittadine의 직접 보유 보통주는 45,858주이며, 아직 권리 확정되지 않은 RSU는 43,001주입니다.
  • 시장 내 매매는 없었으며, 모든 활동은 RSU 자동 정산(거래 코드 “M”)과 관련됩니다.

이번 제출은 임의 매수가 아닌 정기적인 주식 보상 행사임을 나타냅니다. COO의 지분은 다소 증가했지만, 경제적 지출은 전무하므로 외부 투자자에게 주는 신호는 대체로 중립적입니다.

Monopar Therapeutics (MNPR) – Déclaration Formulaire 4 d’initié déposée pour le Directeur des Opérations Andrew Cittadine concernant l’activité du 30 juin 2025.

  • 6 863 actions ordinaires ont été attribuées à Cittadine lors du vesting des Restricted Stock Units (RSU) accordées les 2 février 2022, 1 février 2023 et 4 mars 2025.
  • 2 990 actions ont été retenues pour impôts (code transaction « F »), laissant un net de 3 873 nouvelles actions.
  • La détention directe d’actions ordinaires de Cittadine après les transactions est de 45 858 actions ; il conserve également 43 001 RSU non acquises.
  • Aucun achat ou vente sur le marché ouvert n’a eu lieu ; toute l’activité concerne le règlement automatique des RSU (code transaction « M »).

Le dépôt indique un événement de rémunération en actions de routine plutôt qu’un achat discrétionnaire. Bien que la participation du COO augmente modestement, la dépense économique est nulle ; par conséquent, le signal pour les investisseurs externes est généralement neutre.

Monopar Therapeutics (MNPR) – Insider-Transaktion Form 4 eingereicht für Chief Operating Officer Andrew Cittadine bezüglich der Aktivität am 30. Juni 2025.

  • 6.863 Stammaktien wurden Cittadine bei der Vesting von Restricted Stock Units (RSUs) zugeteilt, die am 2. Feb 2022, 1. Feb 2023 und 4. März 2025 gewährt wurden.
  • 2.990 Aktien wurden zur Steuerabführung einbehalten (Transaktionscode „F“), womit netto 3.873 neue Aktien verbleiben.
  • Cittadines direkte Stammaktien-Beteiligung nach den Transaktionen beträgt 45.858 Aktien; zudem hält er 43.001 nicht freigegebene RSUs.
  • Es fanden keine Käufe oder Verkäufe am offenen Markt statt; alle Aktivitäten beziehen sich auf die automatische RSU-Abrechnung (Transaktionscode „M“).

Die Meldung zeigt ein routinemäßiges Aktienvergütungsereignis und keinen diskretionären Kauf an. Obwohl der Anteil des COO leicht steigt, ist der wirtschaftliche Aufwand null; daher ist das Signal für externe Investoren im Allgemeinen neutral.

Positive
  • COO’s direct ownership increased, modestly reinforcing management-shareholder alignment.
Negative
  • Shares were acquired via vesting, not open-market purchase, so the transaction conveys limited confidence signal.

Insights

TL;DR: Routine RSU vesting—neutral cash-less insider acquisition, minor ownership increase.

The 6,863-share issuance stems from pre-scheduled RSU tranches. Net of tax withholding, Cittadine adds 3,873 shares, taking his direct stake to 45,858 (≈0.4 % of ~11 m shares outstanding). The insider neither paid cash nor sold shares, limiting signaling value. The remaining 43,001 RSUs provide further equity alignment but already factored into fully-diluted share count. Overall impact on valuation, liquidity, or float is immaterial; I classify as neutral.

TL;DR: Equity compensation schedule functioning as designed; governance implications minimal.

The staggered 48-month RSU schedules (2022–2028) support retention of key executives and align incentives without immediate cash cost. Transaction codes “M” and “F” confirm automatic settlement and tax withholding compliance. No 10b5-1 plan is referenced, but the absence of discretionary trades limits potential conflicts. Because the event is routine and disclosed timely, governance risk remains low; therefore, I assign a neutral impact.

Monopar Therapeutics (MNPR) – Transazione insider Form 4 presentata per il Chief Operating Officer Andrew Cittadine relativa all'attività del 30 giugno 2025.

  • Sono state emesse 6.863 azioni ordinarie a Cittadine in seguito al vesting di Restricted Stock Units (RSU) concesse il 2 feb 2022, 1 feb 2023 e 4 mar 2025.
  • Sono state trattenute 2.990 azioni per tasse (codice transazione “F”), lasciando un netto di 3.873 nuove azioni.
  • La partecipazione diretta di Cittadine dopo le transazioni è di 45.858 azioni ordinarie; conserva inoltre 43.001 RSU non ancora vestite.
  • Non si sono verificate compravendite sul mercato aperto; tutta l’attività riguarda il regolamento automatico delle RSU (codice transazione “M”).

Il deposito indica un evento di compensazione azionaria di routine piuttosto che un acquisto discrezionale. Sebbene la quota del COO aumenti leggermente, il costo economico è zero; pertanto, il segnale per gli investitori esterni è generalmente neutro.

Monopar Therapeutics (MNPR) – Transacción insider Formulario 4 presentada para el Director de Operaciones Andrew Cittadine correspondiente a la actividad del 30 de junio de 2025.

  • Se emitieron 6,863 acciones ordinarias a Cittadine tras la consolidación de Unidades de Acciones Restringidas (RSU) otorgadas el 2 de feb 2022, 1 de feb 2023 y 4 de mar 2025.
  • 2,990 acciones fueron retenidas para impuestos (código de transacción “F”), quedando un neto de 3,873 nuevas acciones.
  • La participación directa en acciones ordinarias de Cittadine tras las transacciones es de 45,858 acciones; también conserva 43,001 RSU no consolidadas.
  • No hubo compras ni ventas en el mercado abierto; toda la actividad corresponde a la liquidación automática de RSU (código de transacción “M”).

El informe indica un evento rutinario de compensación en acciones más que una compra discrecional. Aunque la participación del COO aumenta modestamente, el gasto económico es cero; por lo tanto, la señal para los inversores externos es generalmente neutral.

Monopar Therapeutics (MNPR) – 내부자 거래 Form 4 제출 최고운영책임자(Andrew Cittadine)의 2025년 6월 30일 활동에 관한 내용입니다.

  • 6,863주 보통주가 2022년 2월 2일, 2023년 2월 1일, 2025년 3월 4일에 부여된 제한주식단위(RSU)의 권리 확정(vesting)에 따라 Cittadine에게 발행되었습니다.
  • 2,990주가 세금 원천징수(거래 코드 “F”)되어, 순수 3,873주가 신규 발행되었습니다.
  • 거래 후 Cittadine의 직접 보유 보통주는 45,858주이며, 아직 권리 확정되지 않은 RSU는 43,001주입니다.
  • 시장 내 매매는 없었으며, 모든 활동은 RSU 자동 정산(거래 코드 “M”)과 관련됩니다.

이번 제출은 임의 매수가 아닌 정기적인 주식 보상 행사임을 나타냅니다. COO의 지분은 다소 증가했지만, 경제적 지출은 전무하므로 외부 투자자에게 주는 신호는 대체로 중립적입니다.

Monopar Therapeutics (MNPR) – Déclaration Formulaire 4 d’initié déposée pour le Directeur des Opérations Andrew Cittadine concernant l’activité du 30 juin 2025.

  • 6 863 actions ordinaires ont été attribuées à Cittadine lors du vesting des Restricted Stock Units (RSU) accordées les 2 février 2022, 1 février 2023 et 4 mars 2025.
  • 2 990 actions ont été retenues pour impôts (code transaction « F »), laissant un net de 3 873 nouvelles actions.
  • La détention directe d’actions ordinaires de Cittadine après les transactions est de 45 858 actions ; il conserve également 43 001 RSU non acquises.
  • Aucun achat ou vente sur le marché ouvert n’a eu lieu ; toute l’activité concerne le règlement automatique des RSU (code transaction « M »).

Le dépôt indique un événement de rémunération en actions de routine plutôt qu’un achat discrétionnaire. Bien que la participation du COO augmente modestement, la dépense économique est nulle ; par conséquent, le signal pour les investisseurs externes est généralement neutre.

Monopar Therapeutics (MNPR) – Insider-Transaktion Form 4 eingereicht für Chief Operating Officer Andrew Cittadine bezüglich der Aktivität am 30. Juni 2025.

  • 6.863 Stammaktien wurden Cittadine bei der Vesting von Restricted Stock Units (RSUs) zugeteilt, die am 2. Feb 2022, 1. Feb 2023 und 4. März 2025 gewährt wurden.
  • 2.990 Aktien wurden zur Steuerabführung einbehalten (Transaktionscode „F“), womit netto 3.873 neue Aktien verbleiben.
  • Cittadines direkte Stammaktien-Beteiligung nach den Transaktionen beträgt 45.858 Aktien; zudem hält er 43.001 nicht freigegebene RSUs.
  • Es fanden keine Käufe oder Verkäufe am offenen Markt statt; alle Aktivitäten beziehen sich auf die automatische RSU-Abrechnung (Transaktionscode „M“).

Die Meldung zeigt ein routinemäßiges Aktienvergütungsereignis und keinen diskretionären Kauf an. Obwohl der Anteil des COO leicht steigt, ist der wirtschaftliche Aufwand null; daher ist das Signal für externe Investoren im Allgemeinen neutral.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cittadine Andrew

(Last) (First) (Middle)
1000 SKOKIE BLVD SUITE 350

(Street)
WILMETTE IL 60091

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 M 6,863 A (1) 48,848 D
Common Stock 06/30/2025 F 2,990(2) D $35.78 45,858 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 06/30/2025 M 6,863 (3)(4)(5) (3)(4)(5) Common Stock 6,863 $0 43,001 D
Explanation of Responses:
1. Represents shares acquired on vesting and settlement of restricted stock units.
2. Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
3. On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
4. On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
5. On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
/s/ Quan Vu, Attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MNPR shares did COO Andrew Cittadine acquire on 30 June 2025?

He received 6,863 common shares upon RSU vesting.

What is Cittadine’s total direct MNPR shareholding after the Form 4 transactions?

His direct holding is 45,858 shares of common stock.

Were any shares sold on the open market?

No. All activity relates to automatic RSU settlement; there were no open-market sales or purchases.

How many unvested RSUs does Cittadine still hold?

He retains 43,001 Restricted Stock Units scheduled to vest through 31 Dec 2028.

Did the insider pay cash to acquire these shares?

No cash was paid; shares were issued upon vesting, with 2,990 shares withheld to cover taxes.

Is this Form 4 filing considered material for MNPR investors?

The filing reflects routine compensation vesting; it is generally viewed as not materially impactful to MNPR’s valuation.
Monopar Therapeutics Inc

NASDAQ:MNPR

MNPR Rankings

MNPR Latest News

MNPR Latest SEC Filings

MNPR Stock Data

233.97M
4.00M
37.31%
42.25%
0.84%
Biotechnology
Pharmaceutical Preparations
Link
United States
WILMETTE